Up next
Share article
The post has been shared by 0 people.
Mail 0
LinkedIn 0
Twitter 0

The Supply Lines: Which Companies are Making the News?

A roundup of news announcements from DCAT Member Companies in 2023 to date across the bio/pharmaceutical manufacturing value chain: from active pharmaceutical ingredients (small molecules and biologics) to drug products (solid dosage, injectables and specialty dosage forms). Which companies are making the news?

A roundup of news announcements from DCAT Member Companies in 2023 to date across the bio/pharmaceutical manufacturing value chain: from active pharmaceutical ingredients (small molecules and biologics) to drug products (solid dosage, injectables and specialty dosage forms), and packaging. Which companies are making the news?

Companies making news at DCAT Week 2023 
The Drug, Chemical & Associated Technologies Association (DCAT) held its flagship event, DCAT Week, from March 19 to March 23, 2023, where bio/pharma companies and suppliers convened in New York for high-level business meetings, education programs featuring thought leaders, and networking events. With executives from the bio/pharma industry assembled, DCAT Member Companies took the opportunity to highlight recent news from across the bio/pharmaceutical manufacturing value chain.  

In the March 31, 2023, issue of DCAT Value Chain Insights, we featured companies taking to the podium at the DCAT Member Company Announcement Forum, where senior executives highlighted major news from their companies. Participating in the Forum were: Samsung Biologics, WuXi STA, Bachem, Siegfried, WuXi Biologics, Lonza, Catalent, Thermo Fisher Scientific, Flamma, Porton Pharma, BSP Pharmaceuticals, Granules, Meridian Medical Technologies/Kindeva Drug Delivery, and Incog BioPharma Services. See story, Executives Highlight Expansion Plans at the DCAT Member Company Announcement Forum for a roundup of their news announcements.  

In this issue, DCAT Value Chain Insights highlights other companies making the news in chemical/chemical API manufacturing, biologics manufacturing, formulation development and drug-product manufacturing, end-to-end manufacturing (both drug substances and drug products), and packaging. 

See related stories and the companies making the news below: 

From DCAT Week 2023: Supplier News: Chemicals/Chemical API Manufacturing featuring news from PharmaBlock, Seqens, Polpharma API, Cambrex, Actylis, Avantor, Univar, Procos, Maithri Drugs, Dr. Reddy’s Laboratories, Jubilant Biosys, C2 Pharma, and ChemCon. 

From DCAT Week 2023: Supplier News: Biologics Manufacturing featuring news from BioVectra, Scorpius BioManufacturing, Avid Bioservices, IDT Biologika, Landmark Bio, and Mabion. 

From DCAT Week 2023: Supplier News: Formulation Development/Drug Product Manufacturing featuring news from Evonik, Carbogen Amcis, Vetter, Nanoform, Mikart, Ascendia Pharmaceuticals, Bushu Pharma, and Lifecore Biomedical. 

From DCAT Week 2023: Supplier News: End-to-End (Drug Substance and Drug Product) Mfg with news from CordenPharma and BioDuro Sundia.  

From DCAT Week 2023: Supplier News: Packaging featuring news from PCI Pharma Services, Bormioli, and Tedor Pharma Services. 

Recent Feature Articles

CDMOs: Biomanufacturing Expansion Updates

By
Expansions in biomanufacturing (biologic drug substances) continues to be an active area of investment by CDMOs/CMOs. Which companies are expanding? DCAT Value Chain Insights rounds up the latest developments.

Tariffs, Strategies & Biotech: Where Do Things Stand?

By
Biotech industry groups, Biotechnology Innovation Organization (US) and EuropaBio (Europe), weigh in on evolving US trade policy and how to strengthen the life-sciences industry’s competitiveness.

Tariffs & Pharmaceuticals: US Government Takes the Next Step

By
The US Secretary of Commerce has initiated an investigation to determine the effects on US national security of imports of pharmaceuticals, including finished drug products, active pharmaceutical ingredients (APIs), and key starting materials, potentially paving the way for pharmaceutical industry-specific tariffs.

Small-Molecules’ Gain: Trump Signs Executive Order on Drug Pricing

By
President Donald Trump has signed an Executive Order on drug pricing, which calls for eliminating the so-called “pill penalty” under the Medicare Prescription Drug Negotiation Program to equalize the post-approval time frame for drugs subject to negotiation for small-molecule drugs and biologics.